These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23019799)

  • 21. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Ratner RE; Han J; Kim DD; Fineman MS; Baron AD
    Diabetes Care; 2005 May; 28(5):1092-100. PubMed ID: 15855572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
    Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
    Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus.
    Wu JD; Xu XH; Zhu J; Ding B; Du TX; Gao G; Mao XM; Ye L; Lee KO; Ma JH
    Diabetes Technol Ther; 2011 Feb; 13(2):143-8. PubMed ID: 21284481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
    ; Probstfield JL; Hirsch I; O'Brien K; Davis B; Bergenstal R; Kingry C; Khakpour D; Pressel S; Branch KR; Riddle M
    Diabetes Care; 2015 Aug; 38(8):1558-66. PubMed ID: 26068865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.
    Preumont V; Hermans MP; Brichard S; Buysschaert M
    Diabetes Metab; 2010 Sep; 36(4):293-8. PubMed ID: 20447851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes.
    Schernthaner G; Guerci B; Gallwitz B; Rose L; Nicolay C; Kraus P; Kazda C
    Diabetes Metab; 2010 Nov; 36(5):389-94. PubMed ID: 20598608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes.
    Forti A; Garcia EG; Yu MB; Jimenez MC; Brodows RG; Oliveira JH
    Curr Med Res Opin; 2008 Sep; 24(9):2437-47. PubMed ID: 18662495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with exenatide in a routine secondary care diabetes clinic.
    Natarajan B; Edavalath M; Davies J; Jenkins L; Marshall-Richards N; Evans D; Price DE; Bain SC; Stephens JW
    Prim Care Diabetes; 2010 Apr; 4(1):57-60. PubMed ID: 20022310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
    Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
    Fineman MS; Bicsak TA; Shen LZ; Taylor K; Gaines E; Varns A; Kim D; Baron AD
    Diabetes Care; 2003 Aug; 26(8):2370-7. PubMed ID: 12882864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration.
    Buse JB; Han J; Miller S; MacConell L; Pencek R; Wintle M
    Curr Med Res Opin; 2014 Jul; 30(7):1209-18. PubMed ID: 24621255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
    Riddle MC; Henry RR; Poon TH; Zhang B; Mac SM; Holcombe JH; Kim DD; Maggs DG
    Diabetes Metab Res Rev; 2006; 22(6):483-91. PubMed ID: 16634116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
    Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
    Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting.
    Bhushan R; Elkind-Hirsch KE; Bhushan M; Butler WJ; Duncan K; Marrioneaux O
    Diabetes Technol Ther; 2009 Jun; 11(6):353-9. PubMed ID: 19459763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.